The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile

European Journal of Cancer

Volumn 40, Issue 3, 2004, Pages 342-351

  Mathieu, M C ^a   Rouzier, R ^a   Llombart Cussac, A ^b   Sideris, L ^a   Koscielny, S ^a   Travagli, J P ^a   Contesso, G ^a   Delaloge, S ^a   Spielmann, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Istituti Valenciano de Oncologia ^*  (Spain)

Author keywords

Breast cancer; Chemosensitivity; Infiltrating ductal carcinoma; Infiltrating lobular carcinoma; Neoadjuvant chemotherapy; Oestrogen receptor; Progesterone receptor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; DUCTAL BREAST CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBULAR BREAST CARCINOMA; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 1642473193     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.08.015     Document Type: Article

References (39)

1. Sastre-Garau X., Jouve M., Asselain B.et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 77:1996;113-120.
2. Silverstein M.J., Lewinsky B.S., Waisman J.R.et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 73:1994;1673-1677.
3. Toikkanen S., Pylkkanen L., Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br. J. Cancer. 76:1997;1234-1240.
4. Fisher B., Bryant J., Wolmark N.et al. Effect of preoperative chemotherapy on outcome of women with operable breast cancer. J. Clin. Oncol. 16:1998;2672-2685.
5. Rouzier R., Extra J.M., Klijanienko J.et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J. Clin. Oncol. 20:2002;1304-1310.
6. Kuerer H.M., Newman L.A., Smith T.L.et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17:1999;460-469.
7. Amat S., Penault-Llorca F., Cure H.et al. Scarff-Bloom-Richardson (SBR) grading. a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy Int. J. Oncol. 20:2002;791-796.
8. Daidone M.G., Veneroni S., Benini E.et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int. J. Cancer. 84:1999;580-586.
9. Makris A., Powles T.J., Dowsett M.et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 3:1997;593-600.
10. Chang J., Powles T.J., Allred D.C.et al. Biologic markers as predictors of clinical outcome from systeminc therapy for primary operable breast cancer. J. Clin. Oncol. 17:1999;3058-3063.
11. World Health Organization. Histological Typing of Breast Tumours, 2nd edn. Geneva, WHO, 1981.
12. Contesso G., Mouriesse H., Friedman S., Genin J., Sarrazin D., Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer. a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy J. Clin. Oncol. 5:1987;1378-1386.
13. Vincent-Salomon A., Carton M., Freneaux P.et al. ERBB2 overexpression in breast carcinomas. no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy Eur. J. Cancer. 36:2000;586-591.
14. Valero V., Buzdar A.U., McNeese M., Singletary E., Hortobagyi G.N. Primary chemotherapy in the treatment of breast cancer. the university of Texas M. D. Anderson cancer center experience Clin. Breast Cancer. 3(Suppl. 2):2002;S63-S68.
15. Calais G., Berger C., Descamps P.et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer. 74:1994;1283-1288.
16. MacGrogan G., Mauriac L., Durand M.et al. Primary chemotherapy in breast invasive carcinoma. predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi Br. J. Cancer. 74:1996;1458-1465.
17. Young N.A., Mody D.R., Davey D.D. Diagnosis and subclassification of breast carcinoma by fine-needle aspiration biopsy. results of the interlaboratory comparison program in non-gynecologic cytopathology Arch. Pathol. Lab. Med. 126:2002;1453-1457.
18. Makris A., Powles T.J., Ashley S.J.et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann. Oncol. 9:1998;1179-1184.
19. Mauriac L., MacGrogan G., Avril A.et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm. a unicentre randomized trial with a 124-month median follow-up Ann. Oncol. 10:1999;47-52.
20. Bastholt L., Dalmark M., Gjedde S.B.et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer. a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group J. Clin. Oncol. 14:1996;1146-1155.
21. Petit T., Borel C., Ghnassia J.P.et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin. Cancer Res. 7:2001;1577-1581.
22. Smith I.C., Heys S.D., Hutcheon A.W.et al. Neoadjuvant chemotherapy in breast cancer. significantly enhanced response with docetaxel J. Clin. Oncol. 20:2002;1456-1466.
23. The effect of primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27. Special issue: 24th Annual San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment. 69:2001;210. (abstr 215).
24. Bonadonna G., Veronesi U., Brambilla C.et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst. 82:1990;1539-1545.
25. Soomro S., Shousha S., Taylor P., Shepard H.M., Feldmann M. c-erbB-2 expression in different histological types of invasive breast carcinoma. J. Clin. Pathol. 44:1991;211-214.
26. Doglioni C., Dei Tos A.P., Laurino L., Chiarelli C., Barbareschi M., Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 424:1994;47-51.
27. Coradini D., Pellizzaro C., Veneroni S., Ventura L., Daidone M.G. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br. J. Cancer. 87:2002;1105-1111.
28. Frolik D., Caduff R., Varga Z. Pleomorphic lobular carcinoma of the breast. its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas Histopathology. 39:2001;9503-9513.
29. Braud A.C., Asselain B., Scholl S.et al. Neoadjuvant chemotherapy in young breast cancer patients. correlation between response and relapse? Eur. J. Cancer. 35:1999;392-397.
30. Pelissier P., Delaloge S., Mathieu M.C.et al. Intensified anthracyclin doses do not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer. results of a multicenter randomised trial Proc. Am. Soc. Clin. Oncol. 21:2002;64a.
31. Bertheau P., Plassa F., Espie M.et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 360:2002;852-854.
32. Makris A., Powles T.J., Dowsett M., Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet. 345:1995;1181-1182.
33. Kandioler-Eckersberger D., Ludwig C., Rudas M.et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 6:2000;50-56.
34. Geisler S., Lonning P.E., Aas T.et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2001;2505-2512.
35. Bottini A., Berruti A., Bersiga A.et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res. 6:2000;2751-2758.
36. Soong R., Robbins P.D., Dix B.R.et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum. Pathol. 27:1996;1050-1055.
37. Domagala W., Harezga B., Szadowska A., Markiewski M., Weber K., Osborn M. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am. J. Pathol. 142:1993;669-674.
38. Marchetti A., Buttitta F., Pellegrini S.et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 53:1993;4665-4669.
39. Sorlie T., Perou C.M., Tibshirani R.et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10869-10874.